Eps8 Antibody

• 产品编号：CST-12471S      品牌：CST       原厂货号：12471S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

Eps8 抗体能够识别内源性水平的总人Eps8蛋白（p97长亚型和p68短压型都包含在内）。该多克隆抗体是通过用合成肽免疫动物而制备的，该合成肽是人Eps8蛋白氨基末端附近的残基。抗体由蛋白A和肽亲和层析纯化。表皮生长因子受体通路底物8（Eps8的）是一个衔接蛋白，可以被包括EGFR和Src在内的一些受体酪氨酸激酶磷酸化（1,2）。Eps8由N-末端的PTB结构域，以及之后的SH3结构域和C-末端效应结构域组成。Eps8通过加盖肌动蛋白的刺端以及捆绑肌动蛋白亚基的C末端效应子结构域，控制基于肌动蛋白的迁移（3,4）。Eps8的C-末端的α螺旋结构直接与肌动蛋白相互作用，并发挥这些加帽和捆绑功能（5）。肌动蛋白加帽活性需要Eps8通过SH3结构域与接头分子如Abi-1的相互作用而自抑制结合释放（6）。Eps8的SH3结构域也结合RN-tre来调节下游Rab5介导的内吞通路（6）。Eps8通过结合几个受体酪氨酸激酶，如EGFR或FGFR而起作用，以提高受体介导的有丝分裂Rac信号和Rab5内吞作用（6,7）。Eps8的效应子区域对于这个过程是必要的。通过与Abi-1相联系并形成Eps8/Abi-1/Sos-1复合物，Eps8开启生长因子刺激肌动蛋白运动和RAC激活途径（8,9）。已证明，Eps8在丝状伪足突起，细胞迁移，微绒毛形成和粘着这些细胞功能中非常重要的（10-13）。研究表明，通过参与在肌动蛋白细胞功能，Eps8在肿瘤细胞的生长，生存，活力和侵袭中起到了重要作用（14-18）。

1. Fazioli, F. et al. (1993) EMBO J 12, 3799-808.
2. Gallo, R. et al. (1997) Oncogene 15, 1929-36.
3. Disanza, A. et al. (2004) Nat Cell Biol 6, 1180-8.
4. Disanza, A. et al. (2006) Nat Cell Biol 8, 1337-47.
5. Hertzog, M. et al. (2010) PLoS Biol 8, e1000387.
6. Lanzetti, L. et al. (2000) Nature 408, 374-7.
7. Auciello, G. et al. (2013) J Cell Sci 126, 613-24.
8. Scita, G. et al. (1999) Nature 401, 290-3.
9. Innocenti, M. et al. (2003) J Cell Biol 160, 17-23.
10. Welsch, T. et al. (2007) Cancer Lett 255, 205-18.
11. Frittoli, E. et al. (2011) Immunity 35, 388-99.
12. Zwaenepoel, I. et al. (2012) Mol Biol Cell 23, 1080-94.
13. Maa, M.C. et al. (2007) J Biol Chem 282, 19399-409.
14. Xu, M. et al. (2009) Endocrinology 150, 2064-71.
15. Chen, Y.J. et al. (2008) Mol Cancer Ther 7, 1376-85.
16. Yap, L.F. et al. (2009) Oncogene 28, 2524-34.
17. Chen, H. et al. (2010) Cancer Res 70, 9979-90.
18. Funato, Y. et al. (2004) Cancer Res 64, 5237-44.

原厂资料：

Specificity / Sensitivity

Eps8 Antibody recognizes endogenous levels of total human Eps8 protein (both p97 long isoform and p68 short isoform).

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human Eps8 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Epidermal growth factor receptor pathway substrate 8 (Eps8) is an adaptor protein and can be phosphorylated by several receptor tyrosine kinases including EGFR and Src (1,2). Eps8 is composed of an N-terminal PTB domain, followed by an SH3 domain and a C-terminal effector domain. Eps8 controls actin-based motility by capping the barbed end of actin and bundling actin subunits through its C-terminal effector domain (3,4). The C-terminal α hexlical structure of Eps8 interacts directly with actin to exert these capping and bundling functions (5). The actin capping activity requires the release of Eps8 autoinhibitory binding through SH3 domain interaction with an adaptor molecule, such as Abi-1 (6). This SH3 domain of Eps8 also binds to RN-tre to regulate the down stream Rab5-mediated endocytosis pathway (6). Eps8 functions by binding several receptor tyrosine kinases, such as EGFR or FGFR, to enhance receptor mediated mitogenic Rac signaling and Rab5 endocytosis (6,7). The effector region of Eps8 is necessary for this process. By association with Abi-1 and forming the Eps8/Abi-1/Sos-1 complex, Eps8 couples initial growth factor stimulation to actin motility and the Rac activation pathway (8,9). Eps8 has been shown to be important in the cellular function of filopodial protrusions, cell migration, microvilli formation, and focal adhesion (10-13). Research studies have demonstrated that through its involvement in actin related cellular functions, Eps8 plays a role in cancer cell growth, survival, motility, and invasiveness (14-18).

1. Fazioli, F. et al. (1993) EMBO J 12, 3799-808.
2. Gallo, R. et al. (1997) Oncogene 15, 1929-36.
3. Disanza, A. et al. (2004) Nat Cell Biol 6, 1180-8.
4. Disanza, A. et al. (2006) Nat Cell Biol 8, 1337-47.
5. Hertzog, M. et al. (2010) PLoS Biol 8, e1000387.
6. Lanzetti, L. et al. (2000) Nature 408, 374-7.
7. Auciello, G. et al. (2013) J Cell Sci 126, 613-24.
8. Scita, G. et al. (1999) Nature 401, 290-3.
9. Innocenti, M. et al. (2003) J Cell Biol 160, 17-23.
10. Welsch, T. et al. (2007) Cancer Lett 255, 205-18.
11. Frittoli, E. et al. (2011) Immunity 35, 388-99.
12. Zwaenepoel, I. et al. (2012) Mol Biol Cell 23, 1080-94.
13. Maa, M.C. et al. (2007) J Biol Chem 282, 19399-409.
14. Xu, M. et al. (2009) Endocrinology 150, 2064-71.
15. Chen, Y.J. et al. (2008) Mol Cancer Ther 7, 1376-85.
16. Yap, L.F. et al. (2009) Oncogene 28, 2524-34.
17. Chen, H. et al. (2010) Cancer Res 70, 9979-90.
18. Funato, Y. et al. (2004) Cancer Res 64, 5237-44.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody.